<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01543802</url>
  </required_header>
  <id_info>
    <org_study_id>GISG-04</org_study_id>
    <nct_id>NCT01543802</nct_id>
  </id_info>
  <brief_title>Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma</brief_title>
  <acronym>NOPASS</acronym>
  <official_title>A Phase II Window-of-opportunity Study of Preoperative Therapy With Pazopanib (Votrient®) in High-risk Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitätsmedizin Mannheim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum Frankfurt Höchst</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine if a short-term treatment with pazopanib, an oral&#xD;
      drug inhibiting the growth of blood vessel, can reduce the metabolism of soft-tissue sarcomas&#xD;
      and thus facilitate their resection when given prior to surgery. Moreover, the study assesses&#xD;
      the prognostic and predictive value of several new biomarkers (endothelial progenitor cells,&#xD;
      soluble vascular epithelial growth factor),&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow recruitment&#xD;
  </why_stopped>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic response rate</measure>
    <time_frame>day 22-28 (time of post-treatment PET-CT)</time_frame>
    <description>Metabolic response rate is defined as the proportion of patients achieving a metabolic response, i.e. a 50% reduction of the mean standardized uptake value (SUVmean) in the post-treatment compared to the pre-treatment FDG-PET-CT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of tumor tissue with regressive alterations upon resection (&quot;Histopathological Response&quot;)</measure>
    <time_frame>day 28-35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in tumor size in MRI according to RECIST 1.1 criteria</measure>
    <time_frame>baseline and day 22-28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of FDG influx as well as of transport rates k1-k4 and distribution volume VB and fractal dimension in dynamic PET-CT (&quot;Dynamic PET-CT Response&quot;)</measure>
    <time_frame>baseline and day 22-28</time_frame>
    <description>Absolute values of all parameters of FDG kinetics will be used for discriminant analysis evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days for which planned resection is delayed after treatment</measure>
    <time_frame>day 28-35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients in which adverse events occur during treatment</measure>
    <time_frame>day 1-21</time_frame>
    <description>Adverse events are graded according to NCI Common Terminology Criteria for Adverse Events v4.0 (NCI CTCAE v4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local recurrence-free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant recurrence-free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in vascularisation in MRI according to adapted Choi Criteria</measure>
    <time_frame>baseline and day 22-28</time_frame>
    <description>Adapted Choi Criteria as defined ín Stacchiotti S, Collini P, Messina A, Morosi C, Barisella M, Bertulli R, et al. High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 2009;251(2):447-56.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in MRI apparent diffusion coefficient (ADC) values</measure>
    <time_frame>baseline and day 22-28</time_frame>
    <description>ADC values as defined by Dudeck O, Zeile M, Pink D, Pech M, Tunn PU, Reichardt P, et al. Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. J Magn Reson Imaging 2008;27(5):1109-13.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Sarcoma, Soft-tissue</condition>
  <arm_group>
    <arm_group_label>Pazopanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pazopanib</intervention_name>
    <description>Treatment with pazopanib 800 mg qd for 21 days followed by resection of the tumor after a 7-14 days break</description>
    <arm_group_label>Pazopanib</arm_group_label>
    <other_name>Votrient</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent prior to performance of study-specific procedures or&#xD;
             assessments and must be willing to comply with treatment and follow-up.&#xD;
&#xD;
          2. Age ≥ 18 years or legal age of consent if different from 18 years.&#xD;
&#xD;
          3. Non-metastatic primary tumor or locoregional recurrence of histologically confirmed&#xD;
             high-risk (G2/3, diameter ≥5 cm) soft tissue sarcoma (STS) of any location&#xD;
             (extremities, girdle, trunk, retroperitoneum); or metachronous solitary metastasis of&#xD;
             STS for which surgical resection is planned according to the individual choice of the&#xD;
             multidisciplinary treatment team (no grade or size restrictions apply for metastasis).&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          5. Measurable disease according to RECIST 1.1&#xD;
&#xD;
          6. Resectable and solitary tumor, as assessed by the investigator based on staging exams&#xD;
             (CT scan of the chest, CT or MRI of the abdomen, MRI of the limb in case of extremity&#xD;
             STS).&#xD;
&#xD;
          7. Adequate organ system function&#xD;
&#xD;
          8. Women of childbearing potential must have a negative serum pregnancy test within 14&#xD;
             days of first dose of study treatment and agree to use effective contraception, during&#xD;
             the study and until after surgery has been performed.&#xD;
&#xD;
          9. Female subjects who are lactating should discontinue nursing prior to the first dose&#xD;
             of study drug and should refrain from nursing throughout the treatment period and for&#xD;
             14 days following the last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The following tumor types are ineligible&#xD;
&#xD;
               -  Embryonal rhabdomyosarcoma&#xD;
&#xD;
               -  Chondrosarcoma&#xD;
&#xD;
               -  Osteosarcoma&#xD;
&#xD;
               -  Ewing tumors / PNET&#xD;
&#xD;
               -  Gastro-intestinal stromal tumors&#xD;
&#xD;
               -  Dermofibromatosis sarcoma protuberans&#xD;
&#xD;
               -  Inflammatory myofibroblastic sarcoma&#xD;
&#xD;
               -  Malignant mesothelioma&#xD;
&#xD;
          2. Prior malignancy.&#xD;
&#xD;
          3. History or clinical evidence of central nervous system (CNS) metastases or&#xD;
             leptomeningeal carcinomatosis.&#xD;
&#xD;
          4. Prior or concurrent systemic chemotherapy or molecularly targeted therapy for STS or&#xD;
             other malignancies within five years before study entry.&#xD;
&#xD;
          5. Clinically significant gastrointestinal abnormalities that may increase the risk for&#xD;
             gastrointestinal bleeding.&#xD;
&#xD;
          6. Clinically significant gastrointestinal abnormalities that may affect absorption of&#xD;
             investigational product&#xD;
&#xD;
          7. Corrected QT interval (QTc) &gt; 480 msecs (calculation according to Bazett).&#xD;
&#xD;
          8. Presence of uncontrolled infection.&#xD;
&#xD;
          9. History of any one or more of the following cardiovascular conditions within the past&#xD;
             6 months:&#xD;
&#xD;
               -  Cardiac angioplasty or stenting&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Coronary artery bypass graft surgery&#xD;
&#xD;
               -  Symptomatic peripheral vascular disease&#xD;
&#xD;
               -  Class III or IV congestive heart failure, as defined by the New York Heart&#xD;
                  Association (NYHA)&#xD;
&#xD;
         10. Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ≥140 mmHg&#xD;
             or diastolic blood pressure (DBP) of ≥ 90mmHg].&#xD;
&#xD;
         11. Cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism&#xD;
             or untreated deep venous thrombosis (DVT) within the past 6 months.&#xD;
&#xD;
         12. Major surgery or trauma within 28 days prior to first dose of investigational product&#xD;
             and/or presence of any non-healing wound, fracture, or ulcer (procedures such as&#xD;
             catheter placement are not considered to be major surgery).&#xD;
&#xD;
         13. Evidence of active bleeding or bleeding diathesis.&#xD;
&#xD;
         14. Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that&#xD;
             increase the risk of pulmonary hemorrhage.&#xD;
&#xD;
         15. Recent hemoptysis (more than ½ teaspoon of red blood within 8 weeks before first dose&#xD;
             of study drug).&#xD;
&#xD;
         16. Any serious and/or unstable pre-existing medical, psychiatric, or other condition that&#xD;
             could interfere with subject's safety, provision of informed consent, or compliance to&#xD;
             study procedures.&#xD;
&#xD;
         17. Inability or unwillingness to discontinue use of prohibited medications for at least&#xD;
             14 days or five half-lives of a drug (whichever is longer) prior to the first dose of&#xD;
             investigational product and for the duration of the study.&#xD;
&#xD;
         18. Treatment with any of the following therapies:&#xD;
&#xD;
               -  radiation therapy, surgery targeting the lesion under study other than incisional&#xD;
                  biopsy, or tumor embolization, prior to the first dose of pazopanib OR&#xD;
&#xD;
               -  chemotherapy, immunotherapy, biologic therapy, antiangiogenic therapy,&#xD;
                  investigational therapy or hormonal therapy, targeting the lesion under study,&#xD;
                  prior to the first dose of pazopanib OR&#xD;
&#xD;
               -  chemotherapy, immunotherapy, biologic therapy, antiangiogenic therapy,&#xD;
                  investigational therapy or hormonal therapy, targeting any other lesion /&#xD;
                  disease, within 14 days or five half-lives of a drug (whichever is longer) prior&#xD;
                  to the first dose of pazopanib&#xD;
&#xD;
         19. Administration of any non-oncologic investigational drug within 30 days or 5 half&#xD;
             lives whichever is longer prior to receiving the first dose of study treatment.&#xD;
&#xD;
         20. Any ongoing toxicity from prior anti-cancer therapy that is &gt; grade 1 and/or that is&#xD;
             progressing in severity, except alopecia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Hohenberger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Mannheim, Department of Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Frankfurt-Höchst</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>German Cancer Research Center, Medical PET Group - Biological Imaging</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Heidelberg / National Centre for Tumor Diseases</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Mannheim, Dpt. of Surgery</name>
      <address>
        <city>Mannheim</city>
        <zip>68135</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.gisg.de</url>
    <description>General info on German Interdisciplinary Sarcoma Group, under whose auspices the trial is conducted</description>
  </link>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>February 10, 2012</study_first_submitted>
  <study_first_submitted_qc>February 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2012</study_first_posted>
  <last_update_submitted>January 22, 2021</last_update_submitted>
  <last_update_submitted_qc>January 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsmedizin Mannheim</investigator_affiliation>
    <investigator_full_name>Peter Hohenberger</investigator_full_name>
    <investigator_title>Head, Division of Surgical Oncology and Thoracic Surgery</investigator_title>
  </responsible_party>
  <keyword>soft-tissue sarcoma</keyword>
  <keyword>pazopanib</keyword>
  <keyword>antiangiogenetic treatment</keyword>
  <keyword>endothelial progenitor cells</keyword>
  <keyword>preoperative therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

